Insilico Medicine advances Middle East push with UAE AI drug discovery deal

South China Morning PostEN 1 min read 100% complete by Julie ZhangMarch 5, 2026 at 11:30 PM

AI Summary

short article 1 min

Insilico Medicine, a Hong Kong-listed AI drug discovery company, has partnered with the United Arab Emirates’ drug regulator to promote the use of its AI tools in pharmaceutical research across the Middle East. The cooperation agreement was signed in Dubai during the World Health Expo in February. The partnership aims to utilize AI platforms, including generative models and reinforcement learning algorithms, to analyze biological, chemical, and clinical data. This collaboration occurred despite escalating geopolitical tensions in the region, which have impacted the Hang Seng Index. News of the deal initially boosted Insilico's stock price, outperforming the benchmark index.

Key Entities & Roles

Key Player Opposition Context

Hang Seng Index ×230% United States 40% Abu Dhabi 40% Iran 40% Israel 40% Dubai ×250% Emirates Drug Establishment 50% Shaikha Al Mazrouei 60% Middle East 70% United Arab Emirates 80% Insilico Medicine ×390%

Keywords

ai drug discovery 90% artificial intelligence 80% drug regulator 70% pharmaceutical research 60% middle east 60% united arab emirates 50% geopolitical tensions 50% reinforcement learning 40% generative models 40%